Galecto prepares for sale of IPO after capital increase
September 28, 2020
Danish clinical-stage biotech company Galecto, backed by Novo Seeds has raised DKK 400m in a financing round led by Soleus Capital and co-led by Eir Ventures. CEO Hans Schambye states that he believes that this is the last financing before the company plans for an IPO in Sweden or the US. Moreover, he does not rule out a new partnership instead of an IPO.
ⓘ This story was originally featured in our daily M&A Insights newsletter.